Skechers AERO Series Opens New Chapter of Technical Running Innovation
Skechers AERO Spark™ —well-balanced everyday trainer. Built for logging miles with great cushioning underfoot, this go-to trainer can also pick up the pace. It features a dual-density Hyper Burst Ice™ midsole for plush cushioning and support, an all-new Skechers Arch Fit® insole design that is adapted specifically for runners with a more subtle feel, plus the carbon-infused H-plate for a snappy toe-off while also providing the right amount of torsional rigidity. The breathable engineered mesh upper with lace locks ensures a secure fit on every run.
Skechers AERO Burst™ —elevated cushioning, built to go the distance. Designed for long-distance running routines, this well-cushioned style combines premium comfort with performance technologies to help runners feel great mile after mile. It features Hyper Burst Ice™ dual-density midsole foam, a carbon-infused H-plate in the forefoot, and the updated Skechers Arch Fit® support system. The breathable engineered mesh upper and anchored tongue design maximizes comfort through high-mileage training sessions.
"Rooted in our award-winning performance legacy, the Skechers AERO series fuses our signature comfort with innovative technologies and a new aesthetic that elevates Skechers running," said Greg Smith, VP of Product Development and Merchandising for Skechers Performance. "We've fine-tuned every detail of each Skechers AERO design with feedback from top-tier runners through thousands of wear-test miles—from the four-minute milers looking for that quick speed to the ultramarathoners who are pushing the limits on distance. We believe that runners at all levels will love the feel of the Skechers AERO series, and our signature Comfort That Performs will deliver for competitive racers, casual joggers, and everyone in between."
LOS ANGELES, May 07, 2025 --( BUSINESS WIRE )--Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles.
Story Continues
Skechers AERO Tempo™—the launchpad for speed. This high-performance speed day shoe offers a dynamic cushioned design packed with innovation for when you want to pick up the pace. Optimized to deliver a lightweight, yet stable running experience, the energetic design features a breathable woven TPU upper, a Hyper Burst® blend in the midsole, plus an internal full-length carbon-infused H-plate that provides the perfect ratio of rigidity and stiffness. Unique to this style in the range, the Hyper Burst Pro™ sockliner offers underfoot cushioning and responsiveness.
Key signature innovations featured across the range include Skechers Hyper Arc™ technology that adapts to your stride for a more efficient run, plus Goodyear® Performance Outsoles for enhanced traction, stability and durability.
In coordination with the product launch, Skechers will also be sponsoring running events around the globe with activations for runners to discover and experience the Skechers AERO series. From elite competitions to grassroots races, the brand will be present to help celebrate the spirit of running, engage directly with the running community, and make a positive impact while building awareness for the new range of technical running shoes.
The first wave of Skechers AERO Burst and Skechers AERO Spark styles are available now at Skechers retail stores and skechers.com, as well as specialty athletic shops in North America and select global markets. Skechers AERO Tempo will also launch in mid-May in select international markets, and mid-June in the United States.
About SKECHERS U.S.A., Inc.
Skechers (NYSE:SKX), The Comfort Technology Company® based in Southern California, designs, develops and markets a diverse range of lifestyle and performance footwear, apparel and accessories for men, women and children. The Company's collections are available in 180 countries and territories through department and specialty stores, and direct to consumers through skechers.com and more than 5,300 Skechers retail stores. A Fortune 500® company, Skechers manages its international business through a network of wholly-owned subsidiaries, joint venture partners, and distributors. For more information, please visit about.skechers.com and follow us on Facebook, Instagram and TikTok.
About The Goodyear Tire & Rubber Company
Goodyear is one of the world's largest tire companies. It employs about 68,000 people and manufactures its products in 53 facilities in 20 countries around the world. Its two Innovation Centers in Akron, Ohio, and Colmar-Berg, Luxembourg, strive to develop state-of-the-art products and services that set the technology and performance standard for the industry. For more information about Goodyear and its products, go to www.goodyear.com/corporate.
This announcement contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include, without limitation, Skechers' future domestic and international growth, financial results and operations including expected net sales and earnings, its development of new products, future demand for its products, its planned domestic and international expansion, opening of new stores and additional expenditures, and advertising and marketing initiatives. Forward-looking statements can be identified by the use of forward-looking language such as "believe," "anticipate," "expect," "estimate," "intend," "plan," "project," "will," "could," "may," "might," or any variations of such words with similar meanings. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements. Factors that might cause or contribute to such differences include the disruption of business and operations due to the COVID-19 pandemic; delays or disruptions in our supply chain; international economic, political and market conditions including the effects of inflation, tariffs and foreign currency exchange rate fluctuations around the world, the challenging consumer retail markets in the United States, and the impact of wars, acts of war and other conflicts around the world; sustaining, managing and forecasting costs and proper inventory levels; losing any significant customers; decreased demand by industry retailers and cancellation of order commitments due to the lack of popularity of particular designs and/or categories of products; maintaining brand image and intense competition among sellers of footwear for consumers, especially in the highly competitive performance footwear market; anticipating, identifying, interpreting or forecasting changes in fashion trends, consumer demand for the products and the various market factors described above; sales levels during the spring, back-to-school and holiday selling seasons; and other factors referenced or incorporated by reference in Skechers' annual report on Form 10-K for the year ended December 31, 2024 and its quarterly reports on Form 10-Q in 2025. Taking these and other risk factors associated with the COVID-19 pandemic into consideration, the dynamic nature of these circumstances means that what is stated in this press release could change at any time, and as a result, actual results could differ materially from those contemplated by such forward-looking statements. The risks included here are not exhaustive. Skechers operates in a very competitive and rapidly changing environment. New risks emerge from time to time and we cannot predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, you should not place undue reliance on forward-looking statements as a prediction of actual results. Moreover, reported results should not be considered an indication of future performance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250506951768/en/
Contacts
Media Contact:
Jennifer Clay
SKECHERS U.S.A., Inc.
jennc@skechers.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 hours ago
- Business Wire
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ('Avistone'), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study Abstract Number For Publication: 8632 Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic Location: Poster Board, 112 Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common 'off-target' mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ('Avistone') is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.
Yahoo
7 hours ago
- Yahoo
AG1 Expands Into Retail With Costco Wholesale (NasdaqGS:COST) Nationwide Partnership
Costco Wholesale recently announced a noteworthy retail partnership with AG1, marking a significant channel expansion into brick-and-mortar stores. This development, alongside the company's strong financial performance, aligns with the broader 1.7% market rise over the past month. Despite a market climbing 11% over the year, Costco's 4.59% increase is likely bolstered by its revenue growth and innovative product launches, such as the DripDrop® Hydration variety pack. These factors collectively contribute positively to the company's momentum and complement the general upward market trend, illustrating a robust overall positioning. Every company has risks, and we've spotted 1 weakness for Costco Wholesale you should know about. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. The recent retail partnership between Costco and AG1 represents a meaningful channel expansion, potentially enhancing revenue and earnings forecasts. This move into brick-and-mortar stores could elevate sales volumes and support e-commerce initiatives, while further boosting Costco's diversification efforts across its international markets. Over the past five years, Costco's total shareholder return of 262.00% underscores its consistent performance and growth strategies, contrasting the more modest 4.59% increase over the last year compared to a rising market. This longer-term return showcases an impressive trajectory, highlighting Costco's ability to generate significant returns to investors. With the price target set at US$1052.04, slightly above the current share price of US$1010.50, analysts view Costco as being relatively fairly priced, aligning closely with projected earnings growth and market expectations. The slight discount to the price target suggests the potential for alignment between corporate growth initiatives and market sentiment. Relative to the consumer retailing industry, Costco's 1-year return of 4.59% reflects a performance under the market's 11.5% gain; however, its 5-year performance highlights a formidable ability to achieve sustained growth. This context helps investors consider both short-term dynamics and longer-term growth opportunities. Gain insights into Costco Wholesale's past trends and performance with our report on the company's historical track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:COST. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
7 hours ago
- Business Wire
BIOSIG TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of BioSig Technologies, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of BioSig Technologies, Inc. (NasdaqCM: BSGM) and Streamex Exchange Corporation. Upon closing of the proposed transaction, current BioSig shareholders and holders of common stock equivalents will hold 25% of the fully diluted BioSig common stock outstanding. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to BioSig shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
